Monoclonal antibodies (mAbs) directed against IgE (omalizumab) or cytokines such as IL-5 (mepolizumab) or IL-4/IL-13 receptor (dupilumab) have been tested as innovative therapeutic approaches for CRSwNP. This evidence concerns the gene IGHE and chronic rhinosinusitis with nasal polyps.